WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998031794) VEGF-BINDING POLYPEPTIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/031794    International Application No.:    PCT/JP1998/000140
Publication Date: 23.07.1998 International Filing Date: 16.01.1998
IPC:
A61K 38/00 (2006.01), C07K 14/705 (2006.01), C07K 14/71 (2006.01)
Applicants: TOA GOSEI CO., LTD. [JP/JP]; 14-1, Nishishimbashi 1-chome Minato-ku Tokyo 105 (JP) (For All Designated States Except US).
NIWA, Mikio [JP/JP]; (JP) (For US Only).
OKAMOTO, Masaji [JP/JP]; (JP) (For US Only).
MATSUMOTO, Tomoe [JP/JP]; (JP) (For US Only).
SEGAWA, Toshiaki [JP/JP]; (JP) (For US Only)
Inventors: NIWA, Mikio; (JP).
OKAMOTO, Masaji; (JP).
MATSUMOTO, Tomoe; (JP).
SEGAWA, Toshiaki; (JP)
Agent: SHIMIZU, Hatsushi; Kantetsu Tsukuba Building 6F 1-1-1, Oroshi-machi Tsuchiura-shi Ibaraki 300 (JP)
Priority Data:
9/19706 17.01.1997 JP
Title (EN) VEGF-BINDING POLYPEPTIDE
(FR) POLYPEPTIDE LIANT LE FACTEUR VEGF
Abstract: front page image
(EN)A novel polypeptide efficacious as a low molecular VEGF inhibitor usable in the treatment of diseases accompanied by neovascularization, such as solid cancer. This polypeptide is one containing a first immunoglobulin-like domain and a second immunoglobulin-like domain in the extracellular region of KDR which is a VEGF receptor. Although this peptide has a VEGF inhibitory activity, it can be easily expressed by a recombinant DNA because of the low molecular weight thereof compared with the conventional polypeptides. Thus, it is expected to quickly infiltrate into the affected parts.
(FR)Nouveau polypeptide efficace comme inhibiteur de facteur VEGF à faible masse moléculaire, utilisable pour traiter des maladies accompagnées de néovascularisation (par exemple, tumeur solide). Le polypeptide contient un premier domaine de type immunoglobuline et un second domaine de type immunoglobuline dans la région extracellulaire de KDR qui est un récepteur de VEGF. Malgré son activité inhibitrice de VEGF, ce peptide peut être exprimé facilement par un ADN de recombinaison car sa masse moléculaire est faible par rapport aux polypeptides classiques. On s'attend donc à ce que ledit polypeptide infiltre rapidement les zones affectées.
Designated States: JP, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)